Free tool
Drug Trial Radar: Respiratory
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
931
Completed, industry sponsors, Respiratory, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed931
931 trials
Showing 1 to 25, recently updated first.
- Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT04708782 · 598 participants · Start Apr 21, 2021 · Primary completion Feb 2, 2026
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 96 sites in all
- Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent ExacerbationsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT04053634 · 689 participants · Start Aug 26, 2019 · Primary completion Jul 28, 2025
Drug: Benralizumab; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Surprise, Arizona; Little Rock, Arkansas; Los Angeles, California · 342 sites in all
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With AsthmaPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D LLCTeva (TEVA)
NCT06664619 · 649 participants · Start Dec 12, 2024 · Primary completion Oct 26, 2026
Drug: Fp/ABS; FP and 2 more · For: Asthma
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 189 sites in all
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05595642 · 1,380 participants · Start Dec 29, 2022 · Primary completion Jun 24, 2025
Drug: Astegolimab; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Dothan, Alabama; Glendale, Arizona · 348 sites in all
- A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD TreatmentPivotal-lookingCompleted
Eurofarma Laboratorios S.A.Industry
NCT04233190 · 472 participants · Start Apr 19, 2023 · Primary completion Oct 28, 2024
Drug: Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg · For: Asthma Copd
Sites: São Paulo, Brazil
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04701983 · 1,127 participants · Start Dec 16, 2020 · Primary completion Apr 11, 2025
Drug: Itepekimab SAR440340; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Jasper, Alabama; Chandler, Arizona · 232 sites in all
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgePivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05882357 · 67 participants · Start Jun 27, 2023 · Primary completion Sep 4, 2025
Drug: ELX/TEZ/IVA; IVA · For: Cystic Fibrosis
Sites: Nedlands, Australia; Parkville, Australia; South Brisbane, Australia · 19 sites in all
- Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary FibrosisPivotal-lookingCompleted
United TherapeuticsIndustry
NCT05255991 · 597 participants · Start Sep 12, 2022 · Primary completion Jun 30, 2025
Drug: Placebo; Inhaled Treprostinil · For: Idiopathic Pulmonary Fibrosis; Interstitial Lung Disease
Sites: Ciudad Autonoma de Buenos Aires, Argentina; Mar del Plata, Argentina; Córdoba, Argentina · 108 sites in all
- Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT04751487 · 1,234 participants · Start Feb 12, 2021 · Primary completion Apr 21, 2025
Drug: Itepekimab SAR440340; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Phoenix, Arizona; Fresno, California; Palm Springs, California · 238 sites in all
- Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02555683 · 894 participants · Start Dec 11, 2015 · Primary completion Oct 21, 2019
Drug: QAW039; QAW039 and 1 more · For: Asthma
Sites: Birmingham, Alabama; Gilbert, Arizona; Litchfield Park, Arizona · 234 sites in all
- A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT06261957 · 471 participants · Start May 31, 2024 · Primary completion Sep 2, 2025
Drug: Salbutamol HFA-134a; Salbutamol HFA-152a · For: Asthma
Sites: North Hollywood, California; San Mateo, California; Aventura, Florida · 102 sites in all
- A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65Pivotal-lookingCompleted
ALK-Abelló A/SIndustry
NCT07060885 · 327 participants · Start Sep 1, 2025 · Primary completion Aug 31, 2026
Drug: HDM SLIT-tablet (12 SQ-HDM) · For: Allergic Rhinoconjunctivitis; Allergic Rhinitis
Sites: Beijing, China; Fuzhou, China; Guangzhou, China · 30 sites in all
- A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPDPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT04320342 · 3,406 participants · Start Apr 27, 2022 · Primary completion Jan 12, 2026
Drug: Beclomethasone Dipropionate; Glycopyrronium Bromide and 1 more · For: COPD; COPD Exacerbation
Sites: Birmingham, Alabama; Dothan, Alabama; Foley, Alabama · 436 sites in all
- A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPDPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT06208306 · 669 participants · Start Jan 11, 2024 · Primary completion Sep 10, 2026
Drug: Itepekimab (SAR440340); Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Chandler, Arizona; Tucson, Arizona; La Palma, California · 223 sites in all
- Comparison Between CHF5993 pMDI 200/6/12.5 µg HFA-152a VS CHF5993 pMDI 200/6/12.5 µg HFA-134a in Subjects With Asthma (TRECOS).Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT06264674 · 827 participants · Start Nov 27, 2023 · Primary completion Feb 18, 2025
Drug: CHF5993 200/6/12.5 μg pMDI HFA-152a; Inhaler CHF5993 200/6/12.5 μg pMDI HFA-134a · For: Asthma
Sites: Burgas, Bulgaria; Kozloduy, Bulgaria; Momchilgrad, Bulgaria · 118 sites in all
- A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06502366 · 424 participants · Start Jul 22, 2024 · Primary completion Apr 17, 2026
Drug: BDA MDI HFO 160/180 μg; BDA MDI HFA 160/180 μg and 1 more · For: Asthma
Sites: Mobile, Alabama; Sheffield, Alabama; Phoenix, Arizona · 128 sites in all
- STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic AsthmaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06465485 · 504 participants · Start Feb 28, 2024 · Primary completion May 13, 2026
Drug: Benralizumab · For: Severe Eosinophilic Asthma
Sites: Beijing, China; Changsha, China; Chengdu, China · 74 sites in all
- Budesonide/Formoterol Inhalation Powder in Adults With AsthmaPivotal-lookingCompleted
Shanghai Xin Huanghe Pharmaceutical Co., Ltd.Industry
NCT07790159 · 338 participants · Start Feb 21, 2024 · Primary completion Sep 27, 2024
Drug: Budesonide and Formoterol Fumarate; Placebo of Budesonide and Formoterol Fumarate and 2 more · For: Asthma
Sites: Hefei, China; Beijing, China; Xiamen, China · 28 sites in all
- Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil LevelPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT04133909 · 806 participants · Start Oct 30, 2019 · Primary completion Aug 8, 2024
Drug: Mepolizumab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Dothan, Alabama; Huntsville, Alabama · 339 sites in all
- A Study in Patients With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT01245569 · 419 participants · Start Apr 12, 2011 · Primary completion Mar 13, 2012
Drug: Beclomethasone Dipropionate - Formoterol; Fluticasone - Salmeterol · For: Chronic Obstructive Pulmonary Disease
Sites: Aarhus, Denmark; Copenhagen, Denmark; Gentofte Municipality, Denmark · 68 sites in all
- Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT03453112 · 494 participants · Start Oct 9, 2017 · Primary completion Dec 28, 2021
Drug: Foster 100/6µg NEXThaler; Foster 100/6µg pMDI · For: Asthma
Sites: Hefei, China; Beijing, China; Foshan, China · 51 sites in all
HAL AllergyIndustry
NCT06920771 · 691 participants · Start Sep 9, 2024 · Primary completion Mar 30, 2026
Drug: PURETHAL Mites 50,000 AUeq/ml; Biological/Vaccine: Placebo · For: House Dust Mite Allergy; House Dust Mite Rhinitis
Sites: Plovdiv, Bulgaria; Rousse, Bulgaria; Smolyan, Bulgaria · 68 sites in all
- Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of ExacerbationsPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT06040086 · 1,454 participants · Start Sep 22, 2023 · Primary completion Mar 6, 2026
Drug: Placebo; Tozorakimab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Decatur, Alabama; Sheffield, Alabama · 368 sites in all
- Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI)Pivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT03197818 · 708 participants · Start Dec 14, 2016 · Primary completion May 26, 2020
Drug: CHF 5993 100/6/12.5 µg; 160 µg budesonide + 4.5 µg formoterol fumarate · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Beijing, China; Chongqing, China; Fuzhou, China · 64 sites in all
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled CorticosteroidPivotal-lookingCompleted
Chiesi Farmaceutici S.p.A.Industry
NCT05292586 · 1,377 participants · Start Aug 31, 2022 · Primary completion Jun 24, 2024
Drug: Beclomethasone Dipropionate/Formoterol Fumarate; Beclomethasone Dipropionate · For: Asthma
Sites: Mobile, Alabama; Chandler, Arizona; Encinitas, California · 91 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.